# Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis

> **NCT02866903** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hospices Civils de Lyon** · enrollment: 47 (estimated)

## Conditions studied

- Peritoneal Carcinosis

## Interventions

- **DRUG:** intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
- **DRUG:** intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
- **DRUG:** intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy

## Key facts

- **NCT ID:** NCT02866903
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-18
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2017-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02866903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02866903, "Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02866903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*